GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » GlycoMimetics Inc (FRA:GKO) » Definitions » Cyclically Adjusted Price-to-FCF

GlycoMimetics (FRA:GKO) Cyclically Adjusted Price-to-FCF : (As of May. 16, 2024)


View and export this data going back to 2014. Start your Free Trial

What is GlycoMimetics Cyclically Adjusted Price-to-FCF?

Shiller PE for Stocks: The True Measure of Stock Valuation


GlycoMimetics Cyclically Adjusted Price-to-FCF Historical Data

The historical data trend for GlycoMimetics's Cyclically Adjusted Price-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

GlycoMimetics Cyclically Adjusted Price-to-FCF Chart

GlycoMimetics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted Price-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

GlycoMimetics Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted Price-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of GlycoMimetics's Cyclically Adjusted Price-to-FCF

For the Biotechnology subindustry, GlycoMimetics's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


GlycoMimetics's Cyclically Adjusted Price-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, GlycoMimetics's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where GlycoMimetics's Cyclically Adjusted Price-to-FCF falls into.



GlycoMimetics Cyclically Adjusted Price-to-FCF Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted Price-to-FCF takes the Free Cash Flow per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/FCF calculation. Because it considers this 10-year average, it's often referred to as the CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF.

GlycoMimetics's Cyclically Adjusted FCF per Share for the quarter that ended in Mar. 2024 is calculated as:

For example, GlycoMimetics's adjusted Free Cash Flow per Share data for the three months ended in Mar. 2024 was:

Adj_FreeCashFlowPerShare=Free Cash Flow per Share/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=-0.15/129.4194*129.4194
=-0.150

Current CPI (Mar. 2024) = 129.4194.

GlycoMimetics Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201406 0.332 100.560 0.427
201409 -0.199 100.428 -0.256
201412 -0.265 99.070 -0.346
201503 -0.424 99.621 -0.551
201506 -0.279 100.684 -0.359
201509 0.633 100.392 0.816
201512 -0.336 99.792 -0.436
201603 -0.435 100.470 -0.560
201606 -0.319 101.688 -0.406
201609 -0.298 101.861 -0.379
201612 -0.262 101.863 -0.333
201703 -0.363 102.862 -0.457
201706 -0.205 103.349 -0.257
201709 -0.161 104.136 -0.200
201712 -0.208 104.011 -0.259
201803 -0.236 105.290 -0.290
201806 -0.262 106.317 -0.319
201809 -0.201 106.507 -0.244
201812 -0.204 105.998 -0.249
201903 -0.295 107.251 -0.356
201906 -0.235 108.070 -0.281
201909 -0.282 108.329 -0.337
201912 -0.266 108.420 -0.318
202003 -0.073 108.902 -0.087
202006 -0.295 108.767 -0.351
202009 -0.206 109.815 -0.243
202012 -0.167 109.897 -0.197
202103 -0.234 111.754 -0.271
202106 -0.219 114.631 -0.247
202109 -0.279 115.734 -0.312
202112 -0.218 117.630 -0.240
202203 -0.238 121.301 -0.254
202206 -0.294 125.017 -0.304
202209 -0.166 125.227 -0.172
202212 -0.141 125.222 -0.146
202303 -0.180 127.348 -0.183
202306 -0.100 128.729 -0.101
202309 -0.127 129.860 -0.127
202312 -0.108 129.419 -0.108
202403 -0.150 129.419 -0.150

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


GlycoMimetics  (FRA:GKO) Cyclically Adjusted Price-to-FCF Explanation

Compared with the regular Price-to-Free-Cash-Flow, which works poorly for cyclical businesses, the Cyclically Adjusted Price-to-FCF smoothed out the fluctuations of free cash flow during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted Price-to-FCF should give similar results to regular Price-to-Free-Cash-Flow.


GlycoMimetics Cyclically Adjusted Price-to-FCF Related Terms

Thank you for viewing the detailed overview of GlycoMimetics's Cyclically Adjusted Price-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


GlycoMimetics (FRA:GKO) Business Description

Industry
Traded in Other Exchanges
Address
9708 Medical Center Drive, Rockville, MD, USA, 20850
GlycoMimetics Inc is a clinical stage biotechnology company. It is focused on the discovery and development of novel glycomimetic drugs to address unmet medical needs resulting from diseases in which carbohydrate biology plays a key role. Glycomimetics are molecules that mimic the structure of carbohydrates involved in important biological processes. Using expertise in carbohydrate chemistry and knowledge of carbohydrate biology, the company is developing a pipeline of proprietary glycomimetics that may inhibit disease-related functions of carbohydrates, such as the roles it plays in inflammation, cancer, and infection.